Compare Allstate Corp (ALL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allstate Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Allstate Corp trades at $251.71 (market cap $64.77B), while Vertex Pharmaceuticals Incorporated trades at $486.42 (market cap $123.19B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Allstate Corp pays a 1.72% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ALL | VRTX | |
|---|---|---|
Market Cap | $64.77B | $123.19B |
Sector | Financials | Health |
52-Week High | $251.61 | $529.59 |
52-Week Low | $190.00 | $366.54 |
Enterprise Value | $73.56B | $117.93B |
Dividend Yield | 1.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
Vertex Pharmaceuticals (VRTX) trades at $485.39, down 2.24% today but maintains a bullish technical trend with strong support at $486. The company reported robust 2025 results with $12.00B revenue and $3.95B net income, though margins dipped slightly. Recent news highlights a strategic $10B acquisition of Crinetics Pharmaceuticals, expanding its endocrinology portfolio with potential $5B peak sales. Analyst consensus remains strongly bullish with an 83.9% buy rating and $526.50 price target.
Outlook is positive driven by earnings growth and strategic acquisitions, but risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. The stock offers upside to consensus targets but faces volatility near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
